Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PDE6D | O43924 | 1/20 | 0.30 |
| ▸ | PDE6A | P16499 | 1/20 | 0.30 |
| ▸ | PDE6G | P18545 | 1/20 | 0.30 |
| ▸ | PDE6B | P35913 | 1/20 | 0.30 |
| ▸ | PDE6C | P51160 | 1/20 | 0.30 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970413 | 0.89 | CRHR1 (0.36) | CRHR1MAPTMEN1NPC1RAB9A | |
| SCHEMBL968700 | 0.83 | KMT2A (0.33) | CRHR1MAPTMEN1RAB9AKMT2A | |
| SCHEMBL3324518 | 0.81 | PTGS2 (0.38) | PDE2APDE10AMAPTMEN1NPC1 | |
| SCHEMBL13361960 | 0.81 | NPC1 (0.36) | MAPTMEN1NPC1RAB9AKMT2A | |
| SCHEMBL3330603 | 0.81 | ALOX5 (0.33) | MAPTMEN1KMT2ALMNA | |
| SCHEMBL3324746 | 0.81 | PTGS2 (0.35) | CRHR1MEN1KMT2A | |
| SCHEMBL3325965 | 0.79 | KMT2A (0.38) | PDE2APDE10AMAPTMEN1NPC1 | |
| SCHEMBL3325859 | 0.79 | AMY1A (0.32) | CRHR1MAPTMEN1NPC1RAB9A | |
| SCHEMBL3330421 | 0.78 | PSEN1 (0.37) | — | |
| SCHEMBL970040 | 0.77 | ALDH1A1 (0.38) | MAPTMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | CRHR1 1597/4885PDE2A 1/4885PDE10A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.